With 5.1 million patients walking through its doors in the first nine months of 2025, up 7.3 per cent YoY, Burjeel Holdings, MENA region’s super-specialty healthcare services provider, announced its revenue was up 10.6 per cent AED4,099 million (US$1.12 billion).
For the third quarter (Q3), revenue reached a record-high AED1,422 million (US$387.2 million), supported by robust patient growth and improved case mix.
EBITDA improved 17.1 per cent for Q3 to AED320 million (US$87.13 million), while net profit jumped 27.5 per cent to AED175 million (US$47.65 million), underpinned by strong operating leverage and improved capital efficiency.
EBITDA rose 15.3 per cent to AED807 million (US$219.74 million) for 9M 2025, with the EBITDA margin improving to 19.7 per cent YoY from 18.9 per cent. Net profit for the same period rose 18.2 per cent to AED362 million (US$98.57 million).
John Sunil, Chief Executive Officer of Burjeel Holdings, commented: “The third quarter marked a record performance for Burjeel Holdings, underscoring the strength of our network and a leading market position. Strategic investments in recent years have made the group one of the region’s most resilient and trusted healthcare ecosystems, with a well-balanced brand portfolio.
“Our results demonstrate operational efficiency, clinical excellence, and robust financial momentum. The group has established itself as the region’s foremost destination for complex and high-acuity care, encompassing oncology, organ transplantation, and advanced surgical specialties, with world-class capabilities now extending across the GCC.”
Since May 2025, the group temporarily restricted access to Burjeel-branded facilities for certain insurance plans following a policy change by a major Abu Dhabi-based insurer. While this moderated volumes within the basic segment, higher inflows from premium insurers and self-paying patients, along with an increase in complex procedures, sustained overall business momentum.
And Sunil was confident that Burjeel would continue on the upward trend.
“With favourable market dynamics, a strong ramp-up of recently launched assets, and a solid pipeline of expansion projects, we remain confident in our long-term growth trajectory,” he added.
Across the network, more than 67,000 surgeries were performed in nine months, up 10.3 per cent. This included a 41 per cent increase in surgeries related to the group’s oncology services. Bed occupancy rate stood at 67 per cent.
Follow us on
